**
Colossal Biosciences, a biotechnology firm based in Dallas, is at the forefront of an audacious endeavour: the resurrection of extinct species through advanced genetic techniques. With a valuation of $10.2 billion, bolstered by significant investments from high-profile figures like Tiger Woods and Paris Hilton, the company has ignited a heated debate over the ethics and feasibility of “de-extinction.” Following its announcement last year of successfully breeding dire wolf pups from genetically edited grey wolf DNA, Colossal has set its sights on reviving the woolly mammoth and the iconic dodo.
The De-Extinction Initiative
The central premise of Colossal’s work lies in sourcing ancient DNA from fossils and employing cutting-edge gene editing technologies to create hybrid species. The company’s CEO, Ben Lamm, openly embraces comparisons to the fictional world of *Jurassic Park*, suggesting that the film has raised awareness about DNA manipulation among the general populace. “Jurassic Park taught a large population of people that there’s this thing called DNA and humans now can change it,” Lamm remarked, acknowledging the narrative’s dystopian undertones while affirming its educational value.
According to Lamm, the extinction crisis—prompted largely by human activities—creates a “moral obligation” to act. He believes that Colossal’s groundbreaking announcements can foster a renewed interest in conservation, particularly among younger generations in the United States.
The Science Behind De-Extinction
Colossal’s operations are housed within a state-of-the-art, 55,000 square-foot facility that features a striking reception area complete with animatronic displays and models of extinct species. Inside the lab, scientists work meticulously to isolate ancient DNA and edit the genomes of closely related living animals using CRISPR technology. For the dire wolves, 14 specific genes from grey wolves were modified to create larger, snow-coloured hybrids with enhanced cold resistance.
However, the challenges of resurrecting more complex animals like the thylacine, which last roamed the Earth in 1936, are significant. The closest living relative, the fat-tailed dunnart, bears little resemblance to its extinct cousin, necessitating potentially over a million genetic edits. Birds present an even greater hurdle; cloning from skin or hair is far less straightforward than with mammals.
Colossal is also attempting to bring back the dodo and the moa, with the latter representing a formidable challenge—standing at 12 feet tall, this giant flightless bird vanished from New Zealand centuries ago. The team has cultivated primordial germ cells from pigeons, dodo’s closest relative, while incubators in the lab hold eggs from both species.
A Polarising Debate
Despite the buzz surrounding these developments, Colossal’s approach has attracted criticism. Experts argue that the company is merely modifying existing species, rather than truly resurrecting the originals. Vincent Lynch, an evolutionary developmental biologist, expressed concerns that labelling genetically modified wolves as dire wolves is misleading and undermines the scientific integrity of species classification.
Critics also warn that the focus on de-extinction might detract from immediate conservation efforts for endangered species. The notion that we could simply revive extinct animals could foster complacency regarding habitat preservation and species protection—a sentiment echoed by many in the scientific community.
The Future of Conservation
While the allure of de-extinction captivates imaginations, the true potential of Colossal’s technology may lie in its applications for existing endangered species. The company aims to use gene editing to enhance genetic diversity in critically low populations, develop vaccines for diseases affecting Asian elephants, and improve the resilience of vulnerable species like quolls against invasive threats.
Beth Shapiro, Colossal’s chief scientist, emphasised that while the spectacle of resurrecting iconic creatures garners attention, the long-term impact of their research will be in preserving biodiversity and combating extinction on a broader scale.
Why it Matters
The pursuit of de-extinction raises profound questions about our relationship with the natural world and the moral implications of tampering with evolution. As biodiversity continues to decline at an alarming rate, Colossal Biosciences stands at a crossroads, challenging both scientific and ethical boundaries. The company’s initiatives could redefine conservation strategies, but they also risk fostering a dangerous reliance on technology as a substitute for fundamental ecological stewardship. Balancing innovation with responsibility will be crucial as society grapples with these momentous challenges.
